top of page



At the heart of our mission lies the ambition to alleviate the challenges associated with colonoscopies for patients. We're dedicated to pioneering a reliable non-invasive solution that can accurately predict colonoscopy outcomes, lessening the burden on individuals.


Our innovative platform technology not only advances the diagnosis of Inflammatory Bowel Disease (IBD) but also offers promising prospects for tackling various gastrointestinal ailments, including Celiac disease, colorectal cancer (CRC), and irritable bowel syndrome (IBS).


The company's technology is the result of 10 years of R&D in human RNA molecular and computational biology at the Weizmann Institute.

Tracells emerges as a dynamic spinoff company from the Weizmann Institute, pioneering an innovative platform poised to revolutionize the diagnosis of bowel inflammation.


Our cutting-edge technology leverages the human transcriptome of stool samples to accurately diagnose the severity, location, and molecular signatures of bowel inflammation.

With our expertise in intestinal biology, we effectively process clinical stool samples, yielding reliable, robust, and informative measurements. 

The company is the holder of a licensed patent (WO/2023/002491) granted by the Weizmann Institute of Science & Sheba Medical Center in Israel.


​Maya Kahan-Hanum PhD
Maya Kahan-Hanum, PhD

Co-Founder & CEO

10 years drug, clinical development & team leadership at BiomX Ltd. & PolyPid Ltd.

​Yotam Harnik PhD
Yotam Harnik, PhD

Co-Founder & CTO

Expertise in the creation of extensively referenced molecular atlases within the realm of intestinal biology. 10 years in experimental and computational biology.

Prof. Shalev Itzkovitz

Scientific  Founder 

& Board Member

Head of the department of Molecular Cell Biology in the Weizmann Institute.

World leader in the field of spatial transcriptomics and biology of the liver and the gut.

bottom of page